These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37710025)

  • 21. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
    Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
    Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.
    Liu L; Bäcklund LM; Nilsson BR; Grandér D; Ichimura K; Goike HM; Collins VP
    J Mol Med (Berl); 2005 Nov; 83(11):917-26. PubMed ID: 16133418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
    Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
    Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
    Lassman AB; Aldape KD; Ansell PJ; Bain E; Curran WJ; Eoli M; French PJ; Kinoshita M; Looman J; Mehta M; Muragaki Y; Narita Y; Ocampo C; Roberts-Rapp L; Song M; Vogelbaum MA; Walenkamp AME; Wang TJC; Zhang P; van den Bent MJ
    J Neurooncol; 2019 Aug; 144(1):205-210. PubMed ID: 31273577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients.
    Zhao HF; Zhou XM; Wang J; Chen FF; Wu CP; Diao PY; Cai LR; Chen L; Xu YW; Liu J; Li ZY; Liu WL; Chen ZP; Huang GD; Li WP
    J Transl Med; 2021 Aug; 19(1):372. PubMed ID: 34461927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High level EGFR amplification in a newly established glioblastoma cell line 170-MG-BA.
    MacLeod RAF; Schneider B; Sivakova I; Nagel S; Dirks WG; Mraz P; Kubikova E; Perzelova A
    Neoplasma; 2019 Jan; 66(1):109-117. PubMed ID: 30509096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FHL2 interacts with EGFR to promote glioblastoma growth.
    Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
    Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
    Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
    Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
    Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
    Chen JR; Xu HZ; Yao Y; Qin ZY
    Acta Neurol Scand; 2015 Nov; 132(5):310-22. PubMed ID: 25846813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
    Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
    Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.
    Stec WJ; Rosiak K; Siejka P; Peciak J; Popeda M; Banaszczyk M; Pawlowska R; Treda C; Hulas-Bigoszewska K; Piaskowski S; Stoczynska-Fidelus E; Rieske P
    Oncotarget; 2016 May; 7(22):31907-25. PubMed ID: 27004406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
    Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.
    López-Ginés C; Navarro L; Muñoz-Hidalgo L; Buso E; Morales JM; Gil-Benso R; Gregori-Romero M; Megías J; Roldán P; Segura-Sabater R; Almerich-Silla JM; Monleón D; Cerdá-Nicolás M
    Cell Oncol (Dordr); 2017 Aug; 40(4):389-399. PubMed ID: 28631186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
    Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
    Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.
    Nishikawa R; Sugiyama T; Narita Y; Furnari F; Cavenee WK; Matsutani M
    Brain Tumor Pathol; 2004; 21(2):53-6. PubMed ID: 15700833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
    Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
    Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
    Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
    Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.